S100A8/A9: a Janus-faced molecule in cancer therapy and tumorgenesis.

Ghavami S, Chitayat S, Hashemi M, Eshraghi M, Chazin WJ, Halayko AJ, Kerkhoff C
Eur J Pharmacol. 2009 625 (1-3): 73-83

PMID: 19835859 · DOI:10.1016/j.ejphar.2009.08.044

Correlations exist between the abundance of S100 proteins and disease pathologies. Indeed, this is evidenced by the heterodimeric S100 protein complex S100A8/A9 which has been shown to be involved in inflammatory and neoplastic disorders. However, S100A8/A9 appears as a Janus-faced molecule in this context. On the one hand, it is a powerful apoptotic agent produced by immune cells, making it a very fascinating tool in the battle against cancer. It spears the risk to induce auto-immune response and may serve as a lead compound for cancer-selective therapeutics. In contrast, S100A8/A9 expression in cancer cells has also been associated with tumor development, cancer invasion or metastasis. Clearly, there is a dichotomy and future investigations into the role of S100A8/A9 in cancer biology need to consider both sides of the same coin.

MeSH Terms (11)

Animals Apoptosis Calgranulin A Calgranulin B Epithelial Cells Gene Expression Regulation, Neoplastic Humans Immunotherapy Neoplasm Invasiveness Neoplasm Metastasis Neoplasms

Connections (1)

This publication is referenced by other Labnodes entities: